Zidovudine now or later?

Article Abstract:

Asymptomatic HIV-positive patients may benefit from early treatment with zidovudine. HIV is the virus that causes AIDS. Three large-scale studies appear to support the efficacy of early treatment. Treatment should probably begin when CD4 cell counts are greater than 300 to 400 per cubic millimeter. CD4 cells are a type of white blood cell. Blood levels of CD4 cells usually drop substantially during HIV infection. The benefits of early treatment, however, are limited. The onset of AIDS can be delayed, but disease progression seems to be inevitable. New treatments for AIDS will depend on the development of new drugs, research into combination therapy and a better understanding of antiviral activity.

Editorial, Zidovudine

---

Generic HIV drugs - enlightened policy for global health

Article Abstract:

The 2000 International AIDS Conference in Durban, South Africa, focused the world's attention on disparities between rich and poor countries with respect to access to antiretroviral drugs. The benefits of providing effective antiretroviral drugs to patients with human immunodeficiency virus (HIV) infection in developing countries would extend far beyond the direct effects on the health of the patients and such access would almost certainly reduce the overall rates of transmission of HIV.

South Africa, 2000 AD, Dosage and administration, Antiviral agents, Antiretroviral agents, International Conference on AIDS

---

Antiretroviral therapy where resources are limited

Article Abstract:

The challenge of providing care to HIV patients in developing countries is described. Topics include the need for trained medical personnel, infrastructure requirements, antiretroviral resistance, treatment guidelines, providing highly active antiretroviral therapy (HAART), therapy combined with primary care and prevention, and global priorities.

World, Demographic aspects

Similar abstracts:

• Abstracts: 'The patients are delighted at how quickly they have healed'. Bring on the new recruits
• Abstracts: Experts debate widening use of opioid drugs for chronic nonmalignant pain. Accelerated approval scutinized: confirmatory phase 4 studies on new drugs languish
• Abstracts: Defending professional independence: ACCME's proposed new guidelines for commercial support of CME. Separating Continuing Medical Education From Pharmaceutical Marketing
• Abstracts: Systematic identification of drugs that cause birth defects--a new opportunity. Adverse outpatient drug events -- a problem and an opportunity
• Abstracts: The dilemma of Medicaid. Insuring all children - The new political imperative. Medicare and drug pricing

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.